Twin Tree Management
NBIX icon

Twin Tree Management’s Neurocrine Biosciences NBIX Stock Holding History

Twin Tree Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,341
Closed -$841K – 1572
2025
Q4 		$899K Buy
6,341
+1,531
+32% +$222K 0.01% 1034
2025
Q3 		$675K Buy
+4,810
New +$652K ﹤0.01% 1246
2024
Q4 		– Sell
-28,105
Closed -$3.48M – 1810
2024
Q3 		$3.24M Buy
+28,105
New +$3.85M 0.01% 1028
2024
Q2 		– Sell
-19,147
Closed -$2.63M – 1562
2024
Q1 		$2.64M Sell
19,147
-17,764
-48% -$2.43M 0.01% 946
2023
Q4 		$4.86M Buy
36,911
+12,712
+53% +$1.46M 0.01% 883
2023
Q3 		$2.72M Buy
24,199
+19,022
+367% +$2M 0.01% 815
2023
Q2 		$488K Buy
+5,177
New +$506K ﹤0.01% 1059
2022
Q4 		– Sell
-12,477
Closed -$1.32M – 1473
2022
Q3 		$1.32M Buy
12,477
+7,812
+167% +$793K ﹤0.01% 1007
2022
Q2 		$455K Sell
4,665
-7,182
-61% -$663K ﹤0.01% 1303
2022
Q1 		$1.11M Buy
11,847
+9,053
+324% +$767K ﹤0.01% 1261
2021
Q4 		$238K Sell
2,794
-11,800
-81% -$1.09M ﹤0.01% 1411
2021
Q3 		$1.4M Sell
14,594
-8,883
-38% -$839K ﹤0.01% 1117
2021
Q2 		$2.29M Buy
23,477
+17,310
+281% +$1.66M 0.01% 865
2021
Q1 		$600K Buy
6,167
+4,397
+248% +$461K ﹤0.01% 1046
2020
Q4 		$170K Sell
1,770
-5,880
-77% -$568K ﹤0.01% 1112
2020
Q3 		$736K Buy
7,650
+2,479
+48% +$287K ﹤0.01% 929
2020
Q2 		$631K Buy
5,171
+5,121
+10,242% +$566K ﹤0.01% 1123
2020
Q1 		$4K Sell
50
-2,589
-98% -$253K ﹤0.01% 1292
2019
Q4 		$284K Buy
2,639
+122
+5% +$12.8K ﹤0.01% 997
2019
Q3 		$227K Buy
+2,517
New +$235K ﹤0.01% 966
2019
Q2 		– Sell
-2,118
Closed -$174K – 1462
2019
Q1 		$187K Sell
2,118
-1,219
-37% -$102K ﹤0.01% 1038
2018
Q4 		$238K Buy
+3,337
New +$320K ﹤0.01% 1046

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Twin Tree Management's NBIX Position: Q1 2026 in Review

Twin Tree Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,341 shares — an estimated $841K sold.

Twin Tree Management first reported a position in NBIX in Q4 2018 and held it in 22 quarters. The position peaked at $4.86M in Q4 2023. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Twin Tree Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Twin Tree Management sold 6,341 Neurocrine Biosciences shares in Q1 2026, an estimated $841K.
  • Twin Tree Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 22 quarters.
  • Twin Tree Management's Neurocrine Biosciences position peaked at $4.86M in Q4 2023.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.